Literature DB >> 11221834

S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine.

Z Shi1, A Azuma, D Sampath, Y X Li, P Huang, W Plunkett.   

Abstract

The mechanisms of resistance to nucleoside analogues established in preclinical models are rarely found in primary tumors resistant to therapy with these agents. We tested the hypothesis that cells sense sublethal incorporation of analogues into DNA during replication and react by arresting further DNA synthesis and cell cycle progression. After removal of drug, cells may be able to repair damaged DNA and continue proliferation, thus escaping nucleoside analogue toxicity. As a corollary, we evaluated whether dysregulation of this mechanism causes cell death. Using gemcitabine as a model of S-phase-specific nucleoside analogues in human acute myelogenous leukemia ML-1 cells, we found that DNA synthesis decreased, cells arrested in S-phase transit, and 60-70% of the population accumulated in S-phase in response to cytostatic conditions. Proliferation continued after washing the cells into drug-free medium. S-phase-arrested cells were then treated with otherwise nontoxic concentrations of UCN-01, which caused rapid onset of apoptosis without cell cycle progression specifically in cells with an S-phase DNA content. Thus, S-phase arrest by nucleoside analogues sensitizes cells to UCN-01, which appears to activate signaling for death mechanisms and/or inhibit survival pathways. These results differ from those in cells arrested at the G2 checkpoint, in which UCN-01 abrogates cell cycle arrest, permitting cells to progress in the cell cycle before apoptosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11221834

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.

Authors:  Neil Beeharry; Eugenia Banina; James Hittle; Natalia Skobeleva; Vladimir Khazak; Sean Deacon; Mark Andrake; Brian L Egleston; Jeffrey R Peterson; Igor Astsaturov; Timothy J Yen
Journal:  Cell Cycle       Date:  2014-06-23       Impact factor: 4.534

2.  Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.

Authors:  Deepa Sampath; Jorge Cortes; Zeev Estrov; Min Du; Zheng Shi; Michael Andreeff; Varsha Gandhi; William Plunkett
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

3.  Drug-free albumin-triggered sensitization of cancer cells to anticancer drugs.

Authors:  Lian Li; Jiyuan Yang; Sirima Soodvilai; Jiawei Wang; Praneet Opanasopit; Jindřich Kopeček
Journal:  J Control Release       Date:  2018-11-19       Impact factor: 9.776

4.  CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells.

Authors:  Yangzom D Bhutia; Sau Wai Hung; Bhavi Patel; Dylan Lovin; Rajgopal Govindarajan
Journal:  Cancer Res       Date:  2011-02-22       Impact factor: 12.701

5.  Amplification of CD20 Cross-Linking in Rituximab-Resistant B-Lymphoma Cells Enhances Apoptosis Induction by Drug-Free Macromolecular Therapeutics.

Authors:  Lian Li; Jiyuan Yang; Jiawei Wang; Jindřich Kopeček
Journal:  ACS Nano       Date:  2018-04-02       Impact factor: 15.881

Review 6.  Targeting DNA repair and the cell cycle in glioblastoma.

Authors:  Brian M Alexander; Nancy Pinnell; Patrick Y Wen; Alan D'Andrea
Journal:  J Neurooncol       Date:  2011-11-24       Impact factor: 4.130

7.  Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.

Authors:  Ruben A Mesa; David Loegering; Heather L Powell; Karen Flatten; Sonnet J H Arlander; Nga T Dai; Michael P Heldebrant; Benjamin T Vroman; B Douglas Smith; Judith E Karp; Cynthia J Ten Eyck; Charles Erlichman; Scott H Kaufmann; Larry M Karnitz
Journal:  Blood       Date:  2005-03-22       Impact factor: 22.113

8.  ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance.

Authors:  Brett Ewald; Deepa Sampath; William Plunkett
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

9.  Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage.

Authors:  Natalia F Krynetskaia; Manali S Phadke; Sachin H Jadhav; Evgeny Y Krynetskiy
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

10.  Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell lines.

Authors:  Marina Gálvez-Peralta; Nga T Dai; David A Loegering; Karen S Flatten; Stephanie L Safgren; Jill M Wagner; Matthew M Ames; Larry M Karnitz; Scott H Kaufmann
Journal:  Mol Pharmacol       Date:  2008-05-28       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.